BioSpace News Archive

Verismo Therapeutics, a clinical-stage CAR-T company and Penn spinout, and pioneer of the novel KIR-CAR platform technology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to SynKIR-110™ for the treatment of patients with mesothelin-expressing mesotheliomas.

Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today announced it has completed the acquisition of Aceragen, Inc. (“Aceragen”), a privately-held biotechnology company addressing rare, orphan pulmonary and rheumatic diseases for which there are limited or no available treatments.

ProtonDx Ltd, an Imperial College health technology spin-out company delivering cost-effective, ultra-rapid, accurate and portable molecular testing, has been awarded a £365,000 grant from Defra’s Farming Innovation Programme and UKRI’s Transforming Food Production Challenge (Innovate UK) to develop rapid, accurate, point-of-care tests for porcine lung diseases, in collaboration with Imperial College London.

Valneva SE announced its intention to issue and sell, subject to market conditions, approximately $40 million of its ordinary shares in a global offering to specified categories of investors comprised of a public offering of its American Depositary Shares, each representing two ordinary shares, in the United States and a concurrent private placement of its ordinary shares in certain jurisdictions outside of the United States.

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration has approved Dupixent® for the treatment of adult patients with prurigo nodularis.

Children’s Cancer Research Fund recently awarded these eight promising scientists the Emerging Scientist Award, each worth $100,000, to pursue their research in the childhood cancer field:

Eureka Therapeutics, Inc. announced the publication of a study in the New England Journal of Medicine entitled “GPRC5D-Targeted CAR T Cells for Myeloma.” The study was led by Dr. Eric Smith of the Dana-Farber Cancer Institute, Dr. Renier Brentjens of the Roswell Park Comprehensive Cancer Center, and Dr. Sham Mailankody of the Memorial Sloan Kettering Cancer Center.

ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA-targeting therapeutics, announced the expansion of their leadership team through the appointment of Christopher Prentiss as Chief Financial Officer.

The latest market analysis report published by Reports and Data, titled ‘Global Impaired Glucose Tolerance Treatment Market – Forecast to 2030,’ thoroughly examines the Impaired Glucose Tolerance Treatment industry to provide essential data & information for the targeted readers.

The latest market analysis report published by Reports and Data, titled ‘Global Peripheral Artery Disease Treatment Market – Forecast to 2030,’ thoroughly examines the Peripheral Artery Disease Treatment industry to provide essential data & information for the targeted readers.